{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.2880","value":"5.800"},{"groupId":"OG001","spread":"12.2269","value":"7.073"},{"groupId":"OG002","spread":"2.0462","value":"5.529"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Pevonedistat 20 mg/m\\^2, infusion, IV, once, on Day 1 of Part A in participants with normal renal and hepatic function with hematologic malignancies (MDS and AML).","id":"OG000","title":"Part A: Control Arm: Pevonedistat 20 mg/m^2"},{"description":"Pevonedistat 20 mg/m\\^2, infusion, IV, once, on Day 1 of Part A in participants with severe renal impairment with hematologic malignancies (MDS and AML).","id":"OG001","title":"Part A: Renal Arm: Pevonedistat 20 mg/m^2"},{"description":"Pevonedistat 20 mg/m\\^2, infusion, IV, once, on Day 1 of Part A in participants with mild hepatic impairment with hematologic malignancies (MDS and AML).","id":"OG002","title":"Part A: Mild Hepatic Arm: Pevonedistat 20 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK population included all participants who had sufficient dosing in Part A and Part B Cycle 1, had sufficient concentration-time data to permit reliable estimation of PK parameters, and who had not received any excluded concomitant medications through the completion of Part A. Overall number analyzed is the number of participants available for analyses.","reportingStatus":"POSTED","timeFrame":"Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose","title":"Parts A, fu: Fraction of Unbound Drug in Plasma for Pevonedistat","type":"SECONDARY","unitOfMeasure":"percentage of plasma fraction unbound"}